Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer.

CONCLUSIONS: Tisotumab vedotin demonstrated a manageable safety profile and encouraging antitumor activity in patients with previously treated recurrent or metastatic cervical cancer.
PMID: 31796521 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - December 2, 2019 Category: Cancer & Oncology Authors: Hong DS, Concin N, Vergote I, de Bono JS, Slomovitz BM, Drew Y, Arkenau HT, Machiels JP, Spicer J, Jones R, Forster M, Cornez N, Gennigens C, Johnson ML, Thistlethwaite FC, Rangwala RA, Ghatta S, Windfeld K, Harris JR, Lassen UN, Coleman RL Tags: Clin Cancer Res Source Type: research